Biomarker Analysis and Clinical Features Associated With Outcomes in Patients With BRAF-Mutant Melanoma With Brain Metastases Receiving Dabrafenib Plus Trametinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Clin. Cancer Res 2023 Feb 01;29(3)521-531, JS Wilmott, H Tawbi, JA Engh, NM Amankulor, B Shivalingam, H Banerjee, IA Vergara, H Lee, PA Johansson, PM Ferguson, P Saiag, C Robert, JJ Grob, LH Butterfield, RA Scolyer, JM Kirkwood, GV Long, MA DaviesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.